HomeNewsBusinessCoronavirus pandemic | Fate of H-1B visa holders hangs in balance; what does it mean for IT industry’s future?

Coronavirus pandemic | Fate of H-1B visa holders hangs in balance; what does it mean for IT industry’s future?

There are over five lakh Indian H-1B visa holders in the US. Many of them have been waiting to get their green card for more than a decade.

April 12, 2020 / 12:32 IST
Story continues below Advertisement

The fate of H-1B visa holders continues to be dicey even as the Indian government and industry body NASSCOM are talking to the US government regarding the same.

According to a recent news report, the Indian government has asked the Donald Trump administration to extend validity of H-1B and others visas held by Indian nationals.

Story continues below Advertisement

On April 8, Indian Foreign Secretary took up the matter with US Deputy Secretary of State Stephen Biegun.

According to a report in The Times of India, NASSCOM has requested the Department of Homeland Service and the US Citizenship and Immigration Services to extend the 90 days grace period given to leave the country after the visas expire.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show